drugset / Trial / NCT04863794

A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants

NCT04863794 ↗

Phase 1 Completed 21 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelTreatment

Summary

The aim of Study BP41660 is to quantify the amount and concentration of \[89Zr\]DFO-RO7248824 in the brain with positron emission tomography (PET) following a single sub-pharmacological dose of RO7248824 and \[89Zr\]DFO-RO7248824 administered via IT injection to healthy participants.

Timeline

Start
2021-04-29
Primary completion
2022-08-01
Completion
2022-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject RO7248824 Unknown 10 mg Intrathecal

Indications